Skip to content

Metabolomics in Surgical Ophthalmological Patients

Metabolomics in Surgical Ophthalmological Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03098316
Acronym
MISO
Enrollment
90
Registered
2017-03-31
Start date
2017-01-31
Completion date
2018-09-30
Last updated
2017-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Tension Glaucoma, Primary Open-angle Glaucoma

Keywords

Cross sectional studies, Metabolomics, Glaucoma, Low tension glaucoma, Ophthalmologic surgical procedures

Brief summary

Metabolomics consists in the study of metabolites in body fluids or tissues. It investigates the consequences of the activity of genes and proteins. One of its advantages is that it is able to do a simultaneous measurement of metabolic changes in living organisms as a response to a disturbance (disease, diet, environment, others) and because a metabolic profile is summative of all the biochemical processes occurring in the body at a given time, it makes no presumption about the relative importance of these processes. Ultimately it is a fingerprint of the organism's health status, at a given time. Metabolomic analysis of serum, plasma and urine has revealed panels of metabolites that distinguish patients with cardiovascular disease, breast cancer, Parkinson disease, Alzheimer's disease and diabetes from control patients. Regarding ocular diseases only few studies have been published, related to diabetic retinopathy, retinal detachment, age-related macular degeneration, uveitis and glaucoma. Glaucoma is one of the leading causes of blindness in the world, according to the World Health Organization, and there are still no biomarkers that can provide an early diagnosis. Nowadays, glaucoma classification relies substantially in the measurement of intraocular pressure (IOP), which can be rather artificial and also unreliable since IOP values can fluctuate during the day. Moreover, patients with normal IOP values can also develop glaucomatous neuropathy (normal-tension glaucoma, NTG) and progress even when IOP is decreased. Several studies have shown that NTG patients suffer from a systemic vascular dysregulation, with higher rates of systemic hypotension, Raynaud phenomenon and migraine. Hence, other mechanisms than an increased IOP are of importance in the development and progression of glaucoma. Only one metabolome-wide study has been made in glaucoma (Burgess, I.; 2015). In a sample of 72 american patients with primary open angle glaucoma (POAG), the authors found significant differences in comparison to controls. The hypothesis for this study is that glaucoma patients will differ from controls, and POAG patients will differ from NTG patients. The investigators will look into metabolomics as a way to create a method to diagnose and stratify patients, as an add-on or alternative to the currently available diagnostic tools like IOP, functional and structural measurement.

Detailed description

This is a cross sectional study built to compare samples from glaucoma patients undergoing surgery (open-angle glaucoma and normal-tension glaucoma, age and gender matched) with age and gender-matched controls (healthy patients undergoing cataract surgery). For this the investigators will collect plasma, urine and aqueous humor to be analyzed through mass spectrometry and nuclear magnetic resonance spectroscopy. Patients have a night fasting period prior to sample collection, and a lifestyle and food frequency questionnaire is filled to control for nutritional influence on metabolites. Diabetic patients are excluded, since it would confound our analysis.

Interventions

DIAGNOSTIC_TESTMetabolomics analysis of patient samples

Metabolomics analysis of patient samples by mass spectrometry and nuclear magnetic resonance spectroscopy.

Sponsors

FRO (Funds for Research in Ophthalmology, Belgium)
CollaboratorUNKNOWN
Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
60 Years to 90 Years

Inclusion criteria

* glaucoma patients (POAG/NTG): undergoing trabeculectomy, XEN® implantation or cataract surgery * Controls (non glaucoma): undergoing cataract surgery * Caucasian

Exclusion criteria

* Diabetes mellitus * any intra ocular surgery on study eye, other than clear cornea cataract surgery more than one year before * other eye pathologies than the one the surgery is intended for (except refractive error and cataract in glaucoma patients), namely retinopathies, uveitis and other causes for neuropathy.

Design outcomes

Primary

MeasureTime frameDescription
Metabolomics profile of each groupMorning of the surgeryun-targeted metabolomics and identification of metabolites based on exact mass using metabolomics library

Secondary

MeasureTime frameDescription
Surgical success of glaucoma patients12 monthsSuccess is defined as an IOP between 6 and 18 mmHg with a reduction of 30% from baseline, and was sub-categorized as complete success if accomplished without glaucoma medication, qualified success with glaucoma medication, and total success as a combination of both complete and qualified. Eyes needing further glaucoma surgery, IOP ≤5 or \> 18 mmHg on two consecutive visits, or loss of light perception due to glaucoma were considered as failures. Needling of encysted blebs is not considered a failure.

Countries

Belgium

Contacts

Primary ContactSien Boons
sien.boons@uzleuven.be003216340391

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026